Series A Biotech Investors in the US
We've mapped 9 of the most active series a Biotech investors funding founders in the US, with cheques $25K–$18M.
We've mapped 9 of the most active series a Biotech investors funding founders in the US — 9 VCs. Cheque sizes across this segment run $25K–$18M.
When raising series a for a Biotech company in the US, founders should lead with the investors whose stage and cheque size actually match the round — not just the best-known names. 9 of these profiles have been verified in the last review pass. Sign in to see each investor's full thesis, cheque range, and how closely they fit your specific company.
Red Cedar Ventures
Venture subsidiary of the MSU Research Foundation supporting early-stage high-tech startups emerging from Michigan State University. Sign in to see full profile →
Oriza Ventures
Early-stage VC headquartered in Santa Clara investing in US tech startups with cross-border China expansion expertise. Sign in to see full profile →
Emerald Development Manager
New York-based early-stage VC backing elite scientific/engineering teams in cybersecurity/SaaS, biotech/healthcare IT, and clean tech/industrial tech. Sign in to see full profile →
Drads Capital
Boston VC investing in life sciences, biotech and AI; portfolio includes Amylyx, Hyperfine and ROKIT Healthcare. Sign in to see full profile →
DHVC
Palo Alto VC (formerly Danhua Capital) investing in AI, AR/VR, robotics, fintech, healthcare, and enterprise tech. Sign in to see full profile →
Conti
Conti Ventures is the corporate VC unit of Continental Grain; invests in early-stage food and agriculture companies (ag biotech, alt protein, animal health, … Sign in to see full profile →
Amgen Ventures
Corporate venture arm of Amgen (since 2004); early-stage biotech investments in oncology, inflammation, neuroscience, cardiovascular. Sign in to see full profile →
11.2 Capital
Early-stage VC investing in breakthrough deep tech: AI, cybersecurity, quantum, robotics, new space, bioengineering, climate. Sign in to see full profile →
S.R. One
Trans-Atlantic biotech venture capital firm (former GSK venture arm); offices in San Francisco and London; $600M Fund II. Sign in to see full profile →
Looking for the right investors for your specific company? MatchFund ranks every investor against your profile, sector, stage, and traction — not just the obvious ones.
Get matched →Directory last updated: May 2026